MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key trial targets were To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, while one of many exploratory goals https://hectorzhos41852.educationalimpactblog.com/52973773/arecoline-fundamentals-explained